Thursday, July 06, 2017 9:00:25 AM
I recognize there are many differences between Stupp's and NWBO's patient populations both on the plus and minus sides of affecting survival.
Given all the differences I still think using Stupp's curve as an estimate for NWBO's control arm is far better than using UCLA's curve.
UCLA's survival curve looks too strong in fact it tracks loosely with Stupp's MGMT methylated patients which is the best GBM survivors sub-group. This sub-group includes the longest-living psPD patients which should not make it into NWBO's trial.
Here's a survival competitor chart I put together for reference -
Recent NWBO News
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM
